Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/9/2025

Management of Constipation with Polyethylene Glycol

First-Line Treatment Options

  • The American Gastroenterological Association recommends polyethylene glycol (PEG) as a first-line agent for constipation based on moderate quality evidence 1
  • PEG works by drawing water into the intestine to hydrate and soften stool, making it easier to pass 2
  • PEG has been shown to be effective for both short-term and long-term management of constipation with response durability over 6 months 1
  • The National Comprehensive Cancer Network (NCCN) does not recommend docusate for constipation management due to inadequate experimental evidence 3

Evidence Supporting PEG

  • PEG is strongly endorsed in systematic reviews of chronic constipation 4
  • PEG is virtually free from net gain or loss of sodium and potassium, making it safer than some other osmotic agents 4
  • Side effects of PEG may include abdominal distension, loose stool, flatulence, and nausea, but these are generally well-tolerated 1

Algorithmic Approach to Constipation Management

  • The European Society for Medical Oncology (ESMO) recommends starting with PEG 15 gm daily with adequate fluid intake for first-line treatment 1
  • The NCCN recommends encouraging increased fluid intake and physical activity when appropriate 5
  • If constipation persists after 2-3 days, the NCCN suggests assessing for impaction, obstruction, and other treatable causes 5
  • The NCCN recommends considering adding a stimulant laxative such as bisacodyl 10-15 mg daily-TID with a goal of one non-forced bowel movement every 1-2 days 5, 6

Special Considerations

  • The American Gastroenterological Association advises avoiding magnesium-based products in patients with renal insufficiency due to risk of hypermagnesemia 1
  • The ESMO recommends against using bulk laxatives in opioid-induced constipation 4

Constipation Management with PEG and Docusate

Introduction to Constipation Management

  • The National Comprehensive Cancer Network (NCCN) explicitly states that docusate has not shown benefit and is therefore not recommended for constipation management 7
  • Docusate works only as a surfactant to allow water penetration into stool, but this mechanism has proven clinically ineffective 8

Practical Dosing Algorithm

  • Start with PEG (Laxaday) 17 grams (one heaping tablespoon) mixed in 8 oz water twice daily, with a goal of one non-forced bowel movement every 1-2 days 7
  • If constipation persists, add a stimulant laxative (bisacodyl 10-15 mg daily or senna) rather than switching to docusate 7

Critical Pitfalls to Avoid

  • Never use bulk laxatives like psyllium for opioid-induced constipation - they are ineffective and may worsen symptoms 9, 10
  • Avoid magnesium-based osmotic laxatives in patients with renal insufficiency due to hypermagnesemia risk 9

Special Populations

  • For opioid-induced constipation: prophylactic PEG or stimulant laxatives are mandatory from the start of opioid therapy 7, 9, 10
  • For elderly patients: PEG 17 g/day offers efficacy with a good safety profile 9
  • For patients with constipation: osmotic laxatives (PEG, lactulose) or stimulant laxatives (senna, bisacodyl) are preferred options 9, 10

Management of Refractory Constipation

Initial Management

  • The National Comprehensive Cancer Network recommends adding bisacodyl 10-15 mg daily to the current regimen of PEG (Miralax) and senna for patients with refractory constipation, with the option to increase to three times daily if needed 11, 12
  • The combination of osmotic laxatives (PEG) with stimulant laxatives (senna plus bisacodyl) is more effective than either class alone for achieving adequate bowel movements 12

Assessment and Escalation

  • After 2-3 days of the escalated regimen, if symptoms persist, a digital rectal examination should be performed to assess for fecal impaction or obstruction before further escalation 11, 12
  • If impaction is present, suppositories (bisacodyl or glycerine) or enemas (hyperosmotic saline) become first-line therapy as they work more quickly than oral laxatives 12

Alternative Therapies

  • Magnesium salts can be added for their osmotic and stimulant effects if bisacodyl addition is insufficient, but should be avoided in patients with renal impairment due to hypermagnesemia risk 11, 12
  • Lactulose is another osmotic option, but has a 2-3 day latency before effect and commonly causes nausea, abdominal distention, and intolerance to sweet taste 12

Contraindicated Therapies

  • The National Comprehensive Cancer Network explicitly states that docusate (Colace) has inadequate experimental evidence and is not recommended for refractory constipation 11
  • Bulk laxatives, such as psyllium or other fiber supplements, are ineffective for this type of constipation and may worsen symptoms by causing abdominal cramps and bloating 11, 12

Special Considerations

  • Opioid use should be assessed, as opioid-induced constipation requires prophylactic bowel regimens from the start of opioid therapy 11
  • Enemas (fleet, saline, or tap water) or prokinetic agents such as metoclopramide may be useful for persistent constipation, though chronic use is limited by risk of adverse effects 11, 12

REFERENCES

3

adult cancer pain, version 3.2019, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

5

palliative care version 1.2016. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

6

palliative care version 1.2016. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

7

adult cancer pain, version 3.2019, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

11

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2013